中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

重症急性胰腺炎继发持续性炎症-免疫抑制-分解代谢综合征的影响因素及预测模型构建

李婵 梁志海 唐国都

引用本文:
Citation:

重症急性胰腺炎继发持续性炎症-免疫抑制-分解代谢综合征的影响因素及预测模型构建

DOI: 10.3969/j.issn.1001-5256.2023.06.019
基金项目: 

国家自然科学基金 (81970558)

伦理学声明:本研究方案经由广西医科大学第一附属医院医学伦理委员会审批,批号:2023-E107-01。
利益冲突声明:本文不存在任何利益冲突。
作者贡献声明:李婵负责课题设计,收集数据,资料分析,撰写论文;梁志海、唐国都负责拟定写作思路,指导撰写文章并最后定稿。
详细信息
    通信作者:

    唐国都,tguodu02@126.com (ORCID:0000-0002-2849-3244)

Influencing factors for persistent inflammation, immunosuppression, and catabolism syndrome in patients with severe acute pancreatitis and establishment of a predictive model

Research funding: 

National Natural Science Foundation of China (81970558)

More Information
    Corresponding author: TANG Guodu, tguodu02@126.com (ORCID:0000-0002-2849-3244)
  • 摘要:   目的  探讨重症急性胰腺炎(SAP)继发持续性炎症-免疫抑制-分解代谢综合征(PICS)的影响因素,并构建预测模型。  方法  回顾性分析2012年5月—2022年5月广西医科大学第一附属医院163例因SAP收入重症医学科、急诊重症监护室患者的临床资料。依据PICS诊断标准分成2组:PICS组(65例,SAP发生PICS患者)和非PICS组(98例,SAP未发生PICS患者)。符合正态分布的计量资料2组间比较采用成组t检验;不符合正态分布的计量资料2组间比较采用Mann-Whitney U秩和检验。计数资料2组间比较采用χ2检验或Fisher确切概率法。计算方差膨胀因子、相关系数矩阵热图评估变量间多重共线性,采用Lasso回归及多因素Logistic回归筛选出独立危险因素,构建列线图预测模型。采用受试者工作特征曲线、校准曲线及Hosmer-Lemeshow拟合优度检验对模型进行内部验证;采用临床决策曲线评估模型的临床实用性。  结果  单因素分析结果显示,平均动脉压、血红蛋白、红细胞压积(HCT)、中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值(PLR)、尿素、肌酐、格拉斯哥昏迷评分(GCS)、APACHE Ⅱ、SOFA、机械通气、急性呼吸窘迫综合征、急性肾损伤(AKI)、急性肝损伤、低血容量性休克、脓毒症、腹腔高压、腹腔出血、多器官功能障碍综合征在PICS组和非PICS组间比较差异均有统计学意义(P值均<0.05)。Lasso回归筛选的预测变量包括PLR、HCT、APACHE Ⅱ、SOFA、机械通气、AKI、低血容量性休克、腹腔高压。多因素Logistic回归显示,PLR、机械通气、AKI、低血容量性休克是SAP发生PICS的独立危险因素(OR分别为1.006、4.324、3.432、6.910,P值均<0.05)。将上述因素进行模型拟合,经bootstrap内部验证列线图模型曲线下面积为0.874(95%CI:0.822~0.925),校准曲线接近参考曲线,Hosmer-Lemeshow拟合优度检验表明该模型具有良好的拟合度(χ2=8.895,P=0.351)。临床决策曲线分析显示预测模型具有良好的临床实用性。  结论  PLR、机械通气、AKI、低血容量性休克是SAP继发PICS的独立危险因素,构建的列线图模型具有良好的区分度、校准度和临床实用性。

     

  • 图  1  多重共线性检验

    Figure  1.  Test for multicollinearity

    图  2  Lasso回归进行临床特征筛选

    注:a,19个临床特征的系数曲线;b,Lasso回归10倍交叉验证选择临床特征。

    Figure  2.  Selection of potential predictors of PICS in patients with SAP by the Lasso regression

    图  3  SAP患者发生PICS风险预测模型列线图

    Figure  3.  Nomogram of the risk predictive model for PICS in SAP patients

    图  4  SAP患者发生PICS风险预测模型的ROC曲线

    Figure  4.  ROC curve of the risk predictive model for PICS in SAP patients

    图  5  SAP患者发生PICS风险预测模型的校准曲线

    Figure  5.  Calibration curve of the risk predictive model for PICS in SAP patients

    图  6  SAP患者发生PICS风险预测模型的决策曲线

    Figure  6.  Decision curve of the risk predictive model for PICS in SAP patients

    表  1  2组患者一般资料比较

    Table  1.   Comparison of general data between the two groups

    项目 PICS组(n=65) 非PICS组(n=98) 统计值 P
    年龄(岁) 48.00(39.50~59.00) 47.50(37.00~59.25) Z=-0.005 0.996
    性别[例(%)] χ2=0.916 0.339
      男 52(80.0) 72(73.5)
      女 13(20.0) 26(26.5)
    BMI(kg/m2) 23.94(22.00~27.55) 24.98(22.49~27.76) Z=-0.668 0.504
    既往史[例(%)]
      高血压 14(34.7) 34(20.9) χ2=3.255 0.071
      糖尿病 8(12.3) 15(15.3) χ2=0.290 0.590
      腹部疾病 27(41.5) 52(53.1) χ2=1.897 0.168
    SAP病因[例(%)]
      胆源性 5(7.7) 11(1.1) χ2=0.551 0.458
      高脂血症性 17(26.2) 34(34.7) χ2=1.326 0.250
      酒精性 12(18.5) 18(18.4) χ2<0.001 0.988
      创伤性 2(3.1) 3(3.1) χ2<0.001 0.995
      病因不明 29(44.6) 32(32.7) χ2=2.388 0.122
    体温(℃) 37.60(37.00~38.00) 37.50(36.78~38.10) Z=-0.553 0.580
    心率(次/min) 119.43±23.02 112.69±21.48 t=1.881 0.062
    呼吸(次/min) 24.00(20.00~33.00) 26.00(21.50~32.00) Z=-1.064 0.287
    平均动脉压(mmHg) 98.33(80.67~111.67) 104.50(91.59~113.08) Z=-2.207 0.027
    预后
      开放饮食时间(d) 8.00(3.50~13.50) 7.00(3.00~11.00) Z=-1.288 0.198
      病死率[例(%)] 26(40.0) 16(16.3) χ2=11.450 0.001
      住院时间(d) 30.00(22.00~51.00) 22.00(17.00~27.25) Z=-4.666 <0.001
      总费用(万元) 22.23(12.10~39.31) 8.18(6.06~11.86) Z=-6.893 <0.001
    下载: 导出CSV

    表  2  2组患者PICS指标比较

    Table  2.   Comparison of PICS factors between the two groups

    指标 PICS组(n=65) 非PICS组(n=98) Z P
    ICU住院时间(d) 22.00(16.00~42.50) 7.00(4.00~11.00) -8.862 <0.001
    CRP(mg/L) 180.39(120.84~192.00) 190.67(109.04~192.00) -0.265 0.791
    Lym(×109/L) 0.60(0.49~0.75) 1.07(0.72~1.39) -6.547 <0.001
    前白蛋白(g/L) 83.30(52.25~104.15) 110.90(76.73~155.35) -3.488 <0.001
    白蛋白(g/L) 28.30(26.10~31.25) 30.80(27.58~34.78) -3.517 <0.001
    下载: 导出CSV

    表  3  2组患者实验室指标和并发症比较

    Table  3.   Comparison of laboratory data and complication between the two groups

    指标 PICS组(n=65) 非PICS组(n=98) 统计值 P
    WBC(×109/L) 14.46(8.94~18.69) 14.72(10.45~20.09) Z=-0.857 0.391
    Hb(g/L) 87.70(75.05~112.70) 106.60(83.68~126.13) Z=-2.532 0.011
    血小板计数(×109/L) 176.00(117.15~237.20) 196.35(141.93~272.40) Z=-1.366 0.172
    Neu(×109/L) 13.22(8.00~17.00) 12.18(8.38~17.45) Z=-0.095 0.924
    NLR 21.69(11.47~30.30) 12.35(7.41~23.13) Z=-3.383 0.001
    PLR 261.85(198.42~455.46) 207.28(118.19~315.79) Z=-3.210 0.001
    HCT 0.26(0.22~0.36) 0.33(0.26~0.39) Z=-2.649 0.008
    PH 7.44(7.36~7.48) 7.43(7.38~7.48) Z=-0.061 0.951
    PO2(mmHg) 102.00(78.05~136.05) 88.50(71.00~126.03) Z=-1.161 0.246
    PCO2(mmHg) 34.10(30.40~39.40) 35.55(30.00~39.00) Z=-0.278 0.781
    氧合指数 253.00(198.00~332.90) 234.50(184.25~326.50) Z=-0.552 0.581
    血Na(mmol/L) 138.10(133.95~143.20) 137.00(133.80~140.95) Z=-0.727 0.467
    血K(mmol/L) 4.10(3.80~4.52) 4.00(3.59~4.31) Z=-1.466 0.143
    TBil(μmol/L) 26.30(13.30~47.30) 20.55(12.48~35.03) Z=-1.469 0.142
    DBil(μmol/L) 13.30(6.25~28.20) 9.30(5.00~18.75) Z=-1.737 0.082
    BUN(mmol/L) 10.36(6.32~17.51) 6.43(4.15~10.50) Z=-3.250 0.001
    SCr(μmol/L) 152.00(71.50~293.50) 73.50(55.75~141.00) Z=-2.915 0.004
    血淀粉酶(U/L) 76.00(44.00~306.50) 103.00(53.75~389.75) Z=-0.935 0.350
    GCS评分 15.00(13.00~15.00) 15.00(15.00~15.00) Z=-2.973 0.003
    APACHE Ⅱ 13.00(10.00~16.00) 11.00(7.75~14.00) Z=-3.173 0.002
    SOFA 6.00(4.00~10.00) 4.00(2.00~6.00) Z=-4.309 <0.001
    并发症[例(%)]
      机械通气 54(83.1) 34(34.7) χ2=17.785 <0.001
      ARDS 54(83.1) 49(50.0) χ2=17.785 <0.001
      AKI 40(61.5) 23(23.5) χ2=44.521 <0.001
      急性肝损伤 16(24.6) 12(12.2) χ2=105.631 <0.001
      低血容量性休克 15(23.1) 3(3.1) χ2=108.741 <0.001
      脓毒症 37(56.9) 27(27.6) χ2=50.971 <0.001
      肺部感染 63(96.9) 90(91.8) χ2=3.053 0.158
      腹腔高压 34(52.3) 22(22.4) χ2=57.715 <0.001
      腹腔出血 12(18.5) 6(6.1) χ2=118.409 <0.001
      肠瘘 2(3.1) 2(2.0) χ2=0.175 0.524
      MODS 49(75.4) 36(36.7) χ2=26.749 <0.001
    下载: 导出CSV

    表  4  SAP患者发生PICS多因素Logistic回归分析

    Table  4.   Multivariate logistic regression analysis of PICS in patients with SAP

    变量 β P OR 95%CI
    PLR 0.006 <0.001 1.006 1.003~1.009
    HCT -2.810 0.256 0.060 0.000~7.768
    APACHE Ⅱ 0.076 0.124 1.079 0.982~1.195
    SOFA 0.053 0.458 1.055 0.913~1.216
    机械通气 1.464 0.002 4.324 1.723~11.423
    AKI 1.233 0.018 3.432 1.253~9.854
    低血容量性休克 1.933 0.013 6.910 1.685~39.068
    腹腔高压 0.743 0.107 2.102 0.852~5.245
    下载: 导出CSV
  • [1] VANZANT EL, LOPEZ CM, OZRAZGAT-BASLANTI T, et al. Persistent inflammation, immunosuppression, and catabolism syndrome after severe blunt trauma[J]. J Trauma Acute Care Surg, 2014, 76(1): 21-29. DOI: 10.1097/TA.0b013e3182ab1ab5.
    [2] GENTILE LF, CUENCA AG, EFRON PA, et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care[J]. J Trauma Acute Care Surg, 2012, 72(6): 1491-1501. DOI: 10.1097/TA.0b013e318256e000.
    [3] MIRA JC, GENTILE LF, MATHIAS BJ, et al. Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome[J]. Crit Care Med, 2017, 45(2): 253-262. DOI: 10.1097/CCM.0000000000002074.
    [4] NAKAMURA K, OGURA K, NAKANO H, et al. C-reactive protein clustering to clarify persistent inflammation, immunosuppression and catabolism syndrome[J]. Intensive Care Med, 2020, 46(3): 437-443. DOI: 10.1007/s00134-019-05851-3.
    [5] EFRON PA, MOHR AM, BIHORAC A, et al. Persistent inflammation, immunosuppression, and catabolism and the development of chronic critical illness after surgery[J]. Surgery, 2018, 164(2): 178-184. DOI: 10.1016/j.surg.2018.04.011.
    [6] XU D, XUN J. Persistentinflammation-immunosuppression-catabolism syndrome in severe acute pancreatitis[J]. J Chin Pract Diagn Ther, 2018, 32(7): 725-728. DOI: 10.13507/j.issn.1674-3474.2018.07.030.

    徐冬, 荀江. 重症急性胰腺炎并持续性炎症-免疫抑制-分解代谢综合征研究进展[J]. 中华实用诊断与治疗杂志, 2018, 32(7): 725-728. DOI: 10.13507/j.issn.1674-3474.2018.07.030.
    [7] YANG R, DU LL, ZHANG ZD, et al. Clinical observation of severe patients with persistent inflammation immunosuppression catabolism syndrome[J]. China J Emerg Resuscitation Disaster Med, 2021, 16(8): 919-921. DOI: 10.3969/j.issn.1673-6966.2021.08.021.

    杨蓉, 杜玲玲, 章志丹, 等. 重症患者持续性炎症-免疫抑制-分解代谢综合征的临床观察研究[J]. 中国急救复苏与灾害医学杂志, 2021, 16(8): 919-921. DOI: 10.3969/j.issn.1673-6966.2021.08.021.
    [8] KOUPENOVA M, CLANCY L, CORKREY HA, et al. Circulating platelets as mediators of immunity, inflammation, and thrombosis[J]. Circ Res, 2018, 122(2): 337-351. DOI: 10.1161/circresaha.117.310795.
    [9] ZHOU H, MEI X, HE X, et al. Severity stratification and prognostic prediction of patients with acute pancreatitis at early phase: A retrospective study[J]. Medicine (Baltimore), 2019, 98(16): e15275. DOI: 10.1097/md.0000000000015275.
    [10] HAWKINS RB, RAYMOND SL, STORTZ JA, et al. Chronic critical illness and the persistent inflammation, immunosuppression, and catabolism syndrome[J]. Front Immunol, 2018, 9: 1511. DOI: 10.3389/fimmu.2018.01511.
    [11] CHEN MY, CHEN MX, WANG MX, et al. Risk factors for acute kidney injury in severe acute pancreatitis: a Meta-analysis[J]. Chin Gen Pract, 2022, 25(30): 3834-3842. DOI: 10.12114/j.issn.1007-9572.2022.0452.

    陈美颖, 陈木欣, 王明欣, 等. 重症急性胰腺炎患者并发急性肾损伤危险因素的Meta分析[J]. 中国全科医学, 2022, 25(30): 3834-3842. DOI: 10.12114/j.issn.1007-9572.2022.0452.
    [12] WANG X, ZHUANG X, WEI R, et al. Protective effects of Acanthopanax vs. Ulinastatin against severe acute pancreatitis-induced brain injury in rats[J]. Int Immunopharmacol, 2015, 24(2): 285-298. DOI: 10.1016/j.intimp.2014.12.020.
    [13] WANG Y, QI WJ, ZENG YW, et al. Mechanism of action of magnolol in the treatment of acute lung injury in a rat model of severe acute pancreatitis[J]. J Clin Hepatol, 2020, 36(12): 2782-2787. DOI: 10.3969/j.issn.1001-5256.2020.12.028.

    王燕, 齐文杰, 曾亚薇, 等. 厚朴酚治疗重症急性胰腺炎大鼠模型并发急性肺损伤的作用机制[J]. 临床肝胆病杂志, 2020, 36(12): 2782-2787. DOI: 10.3969/j.issn.1001-5256.2020.12.028.
    [14] WANG X, WANG XK, CEN RF, et al. Influence of Xuebijing injection on clinical effects and cellular immune function of patients with severe acute pancreatitis[J]. Chin J New Drugs Clin Rem, 2015, 34(6): 476-479. DOI: 10.14109/j.cnki.xyylc.2015.06.016.

    王雪, 王先坤, 岑荣飞, 等. 血必净注射液对重症急性胰腺炎疗效及患者细胞免疫功能的影响[J]. 中国新药与临床杂志, 2015, 34(6): 476-479. DOI: 10.14109/j.cnki.xyylc.2015.06.016.
    [15] WANG P, LI L, LAN D, et al. Effects of hemofiltration therapy on biochemical indexes, liver and kidney function and inflammatory factors in patients with severe acute pancreatitis complicated with abdominal compartment syndrome[J]. J Clin Exp Med, 2022, 21(4): 384-388. DOI: 10.3969/j.issn.1671-4695.2022.04.014.

    王萍, 李乐, 兰东, 等. 血液滤过治疗对重症急性胰腺炎合并腹腔间隔室综合征患者生化指标、肝肾功能及炎症因子水平的影响[J]. 临床和实验医学杂志, 2022, 21(4): 384-388. DOI: 10.3969/j.issn.1671-4695.2022.04.014.
    [16] SU HY, MO ZX, CHEN R, et al. Effect of thymosin α1 on immunity, metabolism and prognosis in elderly patients with sepsis followed by persistent inflammation, immunosuppression, and catabolism syndrome[J]. J Pract Med, 2018, 34(1): 119-123. DOI: 10.3969/j.issn.1006-5725.2018.01.030.

    苏和毅, 莫泽珣, 陈蕊, 等. 胸腺肽α1干预治疗对脓毒症后的PICS老年患者免疫、代谢功能及预后的影响[J]. 实用医学杂志, 2018, 34(1): 119-123. DOI: 10.3969/j.issn.1006-5725.2018.01.030.
    [17] LUBBERS T, KOX M, DE HAAN JJ, et al. Continuous administration of enteral lipid- and protein-rich nutrition limits inflammation in a human endotoxemia model[J]. Crit Care Med, 2013, 41(5): 1258-1265. DOI: 10.1097/CCM.0b013e31827c0a17.
    [18] ZHU X, PRIBIS JP, RODRIGUEZ PC, et al. The central role of arginine catabolism in T-cell dysfunction and increased susceptibility to infection after physical injury[J]. Ann Surg, 2014, 259(1): 171-178. DOI: 10.1097/SLA.0b013e31828611f8.
  • 加载中
图(6) / 表(4)
计量
  • 文章访问数:  206
  • HTML全文浏览量:  69
  • PDF下载量:  28
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-10-24
  • 录用日期:  2022-11-28
  • 出版日期:  2023-06-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回